Annals of Oncology 25: 1320–1327, 2014
Published online 11 March 2014
Borderline ovarian tumours (BOT) represent a distinct tumour entity of epithelial origin accounting for approximately 10%–20% of all ovarian neoplasms [1, 2]. In contrast to ovarian cancer, they are characterised by the absence of destructive stromal invasion. They are distinct by an epidemiological shift towards younger women and an excellent overall prognosis with a 5-year survival rate of more than 90% across all tumour stages [3–5]. Nevertheless, BOT may recur even after more than 10 years and undergo malignant transformation in selected cases [6].
Conclusions
Despite favourable survival, young BOT patients with child-bearing potential are at higher risk for disease recurrence. However, relapses usually remain BOT in the preserved ovaries as opposed to older patients being at higher risk for malignant transformation in peritoneal or distant localisation. Therefore, fertility-sparing approach can be justified for younger patients after thorough consultation.
jozi-ovari 
Leave a comment